Workflow Services, a US-based platform to enable pharmacist-led clinical services, announced on Tuesday the successful completion of a one-year pilot and a nationwide expansion of its Colorectal Cancer Screening Education Program.
The aim of this initiative is to educate patients about the significance of colorectal cancer screening in the pharmacy setting. The program is intended to bridge the gap in preventive care because of the community pharmacy's unique position as many Americans' most accessible, trusted and frequently visited healthcare provider. In the pilot, 92% of the participating pharmacists reported increased proficiency in their ability to educate patients about the effect of colorectal cancer screening.
Following the pilot program's success, pharmacies across the country will now be able to use the Workflow Services platform to combine colorectal cancer screening education into their patient encounters.
Kevin Houlihan, Workflow Services president and CEO, said: "The data we collected in the pilot shows that we are unlocking a new, impactful healthcare channel. Access is one of the major challenges currently confronting the American healthcare system. And we've seen that by providing pharmacists with the right tools and guardrails in a platform like Workflow Services, we can make a real difference in closing care gaps and driving health outcomes."
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis